Oncosil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorp… Read more
Oncosil Medical Ltd (OSL) - Net Assets
Latest net assets as of December 2025: AU$3.84 Million AUD
Based on the latest financial reports, Oncosil Medical Ltd (OSL) has net assets worth AU$3.84 Million AUD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.13 Million) and total liabilities (AU$3.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$3.84 Million |
| % of Total Assets | 53.8% |
| Annual Growth Rate | 6.39% |
| 5-Year Change | -73.47% |
| 10-Year Change | -79.05% |
| Growth Volatility | 122.21 |
Oncosil Medical Ltd - Net Assets Trend (2005–2025)
This chart illustrates how Oncosil Medical Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncosil Medical Ltd (2005–2025)
The table below shows the annual net assets of Oncosil Medical Ltd from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$3.10 Million | -34.48% |
| 2024-06-30 | AU$4.74 Million | -52.06% |
| 2023-06-30 | AU$9.88 Million | -11.49% |
| 2022-06-30 | AU$11.16 Million | -4.56% |
| 2021-06-30 | AU$11.70 Million | -46.59% |
| 2020-06-30 | AU$21.90 Million | +105.16% |
| 2019-06-30 | AU$10.68 Million | -41.20% |
| 2018-06-30 | AU$18.15 Million | +79.13% |
| 2017-06-30 | AU$10.13 Million | -31.57% |
| 2016-06-30 | AU$14.81 Million | +112.75% |
| 2015-06-30 | AU$6.96 Million | -26.84% |
| 2014-06-30 | AU$9.52 Million | +57.26% |
| 2013-06-30 | AU$6.05 Million | +143.70% |
| 2012-06-30 | AU$2.48 Million | -14.77% |
| 2011-06-30 | AU$2.91 Million | +13.01% |
| 2010-06-30 | AU$2.58 Million | -39.80% |
| 2009-06-30 | AU$4.28 Million | +4.77% |
| 2008-06-30 | AU$4.09 Million | -12.66% |
| 2007-06-30 | AU$4.68 Million | -14.25% |
| 2006-06-30 | AU$5.46 Million | +506.67% |
| 2005-06-30 | AU$899.56K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncosil Medical Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10743135100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$96.43 Million | 3106.96% |
| Other Comprehensive Income | AU$14.14 Million | 455.49% |
| Total Equity | AU$3.10 Million | 100.00% |
Oncosil Medical Ltd Competitors by Market Cap
The table below lists competitors of Oncosil Medical Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
C-SITE Co., Ltd.
KQ:109670
|
$5.44 Million |
|
Gale Pacific Ltd
AU:GAP
|
$5.44 Million |
|
Cosmos Exploration Ltd
AU:C1X
|
$5.44 Million |
|
Blue Energy Ltd
AU:BLU
|
$5.44 Million |
|
InnoTherapy Inc
KQ:246960
|
$5.44 Million |
|
Locafy Ltd
NASDAQ:LCFY
|
$5.43 Million |
|
DILLARDS-A
BE:DL7A
|
$5.43 Million |
|
DS Sigma Holdings Berhad
KLSE:0269
|
$5.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncosil Medical Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,736,409 to 3,103,521, a change of -1,632,888 (-34.5%).
- Net loss of 15,099,844 reduced equity.
- Share repurchases of 12,780,620 reduced equity.
- New share issuances of 12,780,621 increased equity.
- Other comprehensive income increased equity by 6,712,563.
- Other factors increased equity by 6,754,392.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-15.10 Million | -486.54% |
| Share Repurchases | AU$12.78 Million | -411.81% |
| Share Issuances | AU$12.78 Million | +411.81% |
| Other Comprehensive Income | AU$6.71 Million | +216.29% |
| Other Changes | AU$6.75 Million | +217.64% |
| Total Change | AU$- | -34.48% |
Book Value vs Market Value Analysis
This analysis compares Oncosil Medical Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.08x to 1.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-06-30 | AU$0.04 | AU$0.52 | x |
| 2006-06-30 | AU$0.11 | AU$0.52 | x |
| 2007-06-30 | AU$0.08 | AU$0.52 | x |
| 2008-06-30 | AU$0.05 | AU$0.52 | x |
| 2009-06-30 | AU$0.05 | AU$0.52 | x |
| 2010-06-30 | AU$0.03 | AU$0.52 | x |
| 2011-06-30 | AU$0.03 | AU$0.52 | x |
| 2012-06-30 | AU$0.02 | AU$0.52 | x |
| 2013-06-30 | AU$0.04 | AU$0.52 | x |
| 2014-06-30 | AU$0.03 | AU$0.52 | x |
| 2015-06-30 | AU$0.02 | AU$0.52 | x |
| 2016-06-30 | AU$0.03 | AU$0.52 | x |
| 2017-06-30 | AU$0.02 | AU$0.52 | x |
| 2018-06-30 | AU$0.03 | AU$0.52 | x |
| 2019-06-30 | AU$0.01 | AU$0.52 | x |
| 2020-06-30 | AU$0.03 | AU$0.52 | x |
| 2021-06-30 | AU$0.01 | AU$0.52 | x |
| 2022-06-30 | AU$0.01 | AU$0.52 | x |
| 2023-06-30 | AU$0.01 | AU$0.52 | x |
| 2024-06-30 | AU$0.00 | AU$0.52 | x |
| 2025-06-30 | AU$0.28 | AU$0.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncosil Medical Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -486.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1289.71%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 2.30x
- Recent ROE (-486.54%) is below the historical average (-79.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -2.94% | 0.00% | 0.00x | 1.05x | AU$-116.38K |
| 2006 | -2.35% | -8.47% | 0.18x | 1.50x | AU$-673.74K |
| 2007 | -35.77% | -95.22% | 0.25x | 1.50x | AU$-2.14 Million |
| 2008 | -67.70% | -134.06% | 0.33x | 1.51x | AU$-3.18 Million |
| 2009 | -10.28% | -19.11% | 0.44x | 1.22x | AU$-868.21K |
| 2010 | -66.42% | -82.03% | 0.71x | 1.15x | AU$-1.97 Million |
| 2011 | -50.05% | 0.00% | 0.00x | 1.04x | AU$-1.75 Million |
| 2012 | -17.36% | -262.80% | 0.06x | 1.02x | AU$-679.28K |
| 2013 | -14.53% | -998.86% | 0.01x | 1.03x | AU$-1.48 Million |
| 2014 | -72.17% | -2173.45% | 0.03x | 1.01x | AU$-7.82 Million |
| 2015 | -41.36% | -104.43% | 0.37x | 1.06x | AU$-3.58 Million |
| 2016 | -32.20% | -124.29% | 0.24x | 1.07x | AU$-6.25 Million |
| 2017 | -69.23% | -199.66% | 0.30x | 1.16x | AU$-8.03 Million |
| 2018 | -47.04% | -192.00% | 0.22x | 1.10x | AU$-10.36 Million |
| 2019 | -80.25% | -236.27% | 0.31x | 1.09x | AU$-9.63 Million |
| 2020 | -19.46% | -154.20% | 0.11x | 1.10x | AU$-6.45 Million |
| 2021 | -89.21% | -4896.98% | 0.02x | 1.21x | AU$-11.60 Million |
| 2022 | -96.10% | -4627.92% | 0.02x | 1.17x | AU$-11.84 Million |
| 2023 | -114.80% | -3085.04% | 0.03x | 1.16x | AU$-12.33 Million |
| 2024 | -251.54% | -2306.09% | 0.08x | 1.42x | AU$-12.39 Million |
| 2025 | -486.54% | -1289.71% | 0.16x | 2.30x | AU$-15.41 Million |
Industry Comparison
This section compares Oncosil Medical Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $14,750,885
- Average return on equity (ROE) among peers: -315.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncosil Medical Ltd (OSL) | AU$3.84 Million | -2.94% | 0.86x | $5.44 Million |
| 4DMEDICAL Ltd (4DX) | $926.64K | -85.93% | 0.18x | $1.08 Billion |
| Adherium Ltd (ADR) | $34.53 Million | -3.63% | 0.08x | $2.37 Million |
| Aroa Biosurgery Ltd (ARX) | $-22.65 Million | 0.00% | 0.00x | $91.94 Million |
| Atomo Diagnostics Ltd (AT1) | $34.48 Million | -26.73% | 0.05x | $8.72 Million |
| Control Bionics Ltd (CBL) | $6.09 Million | -15.97% | 0.04x | $4.72 Million |
| Cardiex Ltd (CDX) | $3.03 Million | -101.61% | 0.73x | $4.25 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $12.44 Million |
| Cochlear Ltd (COH) | $75.42 Million | 53.19% | 1.13x | $6.95 Billion |
| Cleo Diagnostics Ltd (COV) | $5.83 Million | -68.54% | 0.19x | $23.23 Million |
| Conneqt Health Limited (CQT) | $633.50K | -2871.98% | 13.72x | $4.66 Million |